Aileron Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aileron Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2016 to Q3 2024.
  • Aileron Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $508K, a 122% increase year-over-year.
  • Aileron Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $1.25M, a 6.7% decline year-over-year.
  • Aileron Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.19M, a 42.9% decline from 2022.
  • Aileron Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.08M, a 7.83% decline from 2021.
  • Aileron Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.26M, a 19.4% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.25M $508K +$279K +122% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $975K $326K +$26K +8.67% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $949K $150K -$241K -61.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $1.19M $270K -$154K -36.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 $1.34M $229K -$213K -48.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $1.56M $300K -$228K -43.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $1.79M $391K -$298K -43.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $2.08M $424K -$183K -30.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 $2.27M $442K -$219K -33.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-13
Q2 2022 $2.49M $528K +$167K +46.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $2.32M $689K +$58K +9.19% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $2.26M $607K +$244K +67.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 $2.02M $661K +$196K +42.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $1.82M $361K -$199K -35.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $2.02M $631K +$126K +25% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $1.89M $363K -$116K -24.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 $2.01M $465K -$149K -24.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $2.16M $560K +$100K +21.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $2.06M $505K -$58K -10.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 $2.12M $479K -$112K -19% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-24
Q3 2019 $2.23M $614K +$26K +4.42% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $2.2M $460K -$874K -65.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $3.08M $563K -$204K -26.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $3.28M $591K -$72K -10.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 $3.35M $588K -$28K -4.55% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $3.38M $1.33M +$1.06M +389% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $2.32M $767K +$570K +289% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $1.75M $663K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-29
Q3 2017 $616K +$427K +226% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $273K +$106K +63.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $197K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q3 2016 $189K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $167K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.